Modality
ERT
MOA
WRNi
Target
CD123
Pathway
RAS/MAPK
EpilepsySLE
Development Pipeline
Preclinical
Dec 2019
→ Jan 2029
PreclinicalCurrent
NCT07881271
1,152 pts·Epilepsy
2019-12→2029-01·Terminated
NCT06092455
824 pts·Epilepsy
2024-03→TBD·Terminated
1,976 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-262.8y awayInterim· Epilepsy
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Preclinical
Termina…
Preclinical
Termina…
Catalysts
Interim
2029-01-26 · 2.8y away
Epilepsy
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07881271 | Preclinical | Epilepsy | Terminated | 1152 | HbA1c |
| NCT06092455 | Preclinical | Epilepsy | Terminated | 824 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| Pemitapinarof | BeiGene | Approved | KRASG12C | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| VKT-4052 | Viking Therapeutics | Phase 2/3 | TNFα | |
| Zorizumab | Beam | Approved | CD123 | |
| RCK-1666 | Rocket Pharma | Approved | CD38 |